Theralase Technologies Inc. V.TLT

Possible TR @450-days of 70%+

[ScienceFirst]

CR @450-days was 28%
PR @450-days was 10%
TR @450-days was 38%

We got these results while 50% of our 25 first patients have been undertreated but, still, we managed to obtain superior CR @90-days (53% versus 41%) and CR @450-days (28% versus 19%) results than Keytruda.  Keytruda was discontinued due to adverse events reactions in 11% of patients.  

Moreover, Keytruda does patients discrimination as less than 25% of patients have the appropriate genetic profile suited for Keytruda.

Rough assumptions:

Considering that 50% of our 25 first patients have been undertreated but that we managed to obtain a CR of 28% @450-days, with a full set of optimized patients, we could roughly estimate that we could have doubled our CR @450-days @50%+, with a TR @70%+, more or less.

Clear candidate to FDA designation(s).

[BlueFranky]

Excellent post  SF! Thank you

[ScienceFirst]

I found this interesting statement in ImmunityBio's news release on their BCG-Unresponsive trial. ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer ... In addition, for patients with papillary disease, a disease-free survival rate at 18